P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections. According to GlobalData, Phase II drugs for Staphylococcus aureus Infections have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how P-128’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
P-128 overview
P-128 is under development for the treatment of bacteremia and staphylococcus aureus Infections. The drug is administered as gel through topical route. It is a recombinant chimeric anti-staphylococcal protein formed by fusing the tail-associated muralytic enzyme from a lytic bacteriophage (phage K)10 with the Src Homology (SH3b) staphylococcal cell wall-binding domain of lysostaphin. The drug candidate targets staphylococcal peptidoglycan. It was also under development for chronic venous leg ulcers, pseudomonas aeruginosa infections in burns and wounds, gram-negative bacterial infections and tuberculosis, nasal decolonization of Staphylococcal infections including methicillin-resistant Staphylococcus aureus (MRSA).
GangaGen Biotechnologies overview
GangaGen Biotechnologies(GBPL) is Engineering Novel Treatments For Drug Resistant Bacterial Infections. GBPL is headquartered Bengaluru, Karnataka, India.
For a complete picture of P-128’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
